Through the use of our unique drug delivery technology, LiquiXR®, Tris Pharma is pioneering strategies to attack a variety of diseases. Extending our successful track record of 8 approved NDAs, Tris Pharma’s rich pipeline of product candidates demonstrates our leadership in developing innovative drugs that meet otherwise unmet patient needs.

Tris Brand Pipeline Overview

Branded Pipeline Approval Stage 1
Branded Pipeline Approval Stage 2

ADHD, attention deficit hyperactivity disorder; CNS, central nervous system; NDA, new drug application.

Contact us

Interested in learning more about our products, pipeline, and partnerships?

Required fields are indicated with "*".